background
understand
immun
respons
middl
east
respiratori
syndrom
mer
import
develop
treatment
prevent
measur
investig
spectrum
immun
respons
occur
patient
mer
earli
period
infect
method
obtain
peripher
blood
sampl
hospit
patient
recruit
epidem
occur
south
korea
plasma
cytokineschemokin
antibodi
quantifi
virusspecif
cell
examin
intracellular
cytokin
stain
stimul
peripher
blood
mononuclear
cell
overlap
peptid
span
whole
viru
structur
protein
result
acut
phase
infect
elev
level
plasma
proinflammatori
cytokineschemokin
detect
proport
sever
diseas
distinct
high
frequenc
mer
coronavirusreact
cell
also
observ
patient
severemoder
ill
wherea
antibodi
tcell
respons
minim
detect
stage
convalesc
phase
diseas
severitydepend
antibodi
respons
emerg
antigenreact
cell
identifi
tcell
subset
cell
belong
thelper
type
cytotox
cell
subtyp
cell
respond
preferenti
viral
protein
compar
emn
protein
especi
acut
stage
slightli
cell
recogn
emn
protein
compar
protein
convalesc
phase
conclus
find
show
associ
earli
tcell
respons
sever
infect
also
provid
basic
inform
may
help
prepar
effect
control
strategi
mer
human
middl
east
respiratori
syndrom
coronaviru
merscov
mainli
caus
respiratori
ill
wide
rang
clinic
sever
vari
asymptomat
sever
pneumonia
respiratori
failur
clinic
characterist
mer
biolog
caus
viru
well
document
pathogenesi
host
immun
respons
merscov
infect
poorli
investig
hamper
develop
therapeut
prevent
measur
recent
studi
demonstr
strong
antibodi
respons
develop
patient
week
ill
antibodi
respons
like
correl
elimin
viru
bodi
elev
serum
level
proinflammatori
cytokin
chemokin
interleukin
il
also
observ
patient
earli
period
sever
infect
furthermor
tcell
respons
merscov
recent
measur
mer
survivor
late
convalesc
period
associ
diseas
cours
analyz
howev
inform
lack
regard
tcell
respons
patient
acut
stage
infect
vitro
anim
studi
show
merscov
preferenti
infect
respiratori
epitheli
cell
inhibit
type
interferon
respons
cell
antibodi
reveal
particip
clear
invad
merscov
virion
protect
subsequ
infect
respect
also
report
local
immun
respons
like
play
role
pulmonari
patholog
sever
howev
remain
seen
whether
inform
obtain
anim
studi
also
appli
human
studi
examin
variou
immunolog
featur
especi
tcell
respons
use
blood
sampl
obtain
patient
acut
earli
convalesc
stage
merscov
infect
data
provid
basic
inform
j
r
r
c
l
e
understand
role
immun
respons
diseas
process
mer
recruit
patient
mer
hospit
nation
medic
center
nmc
seoul
outbreak
south
korea
merscov
infect
confirm
realtim
reversetranscript
polymeras
chain
reaction
rtpcr
clinic
inform
includ
laboratori
data
individu
patient
provid
supplementari
tabl
peripher
blood
collect
patient
acut
convalesc
phase
infect
studi
acut
phase
defin
period
onset
symptom
peak
ill
usual
within
week
onset
symptom
convalesc
phase
defin
period
immedi
neg
convers
realtim
rtpcr
usual
week
symptom
onset
studi
approv
nmc
ethic
committe
peripher
blood
mononuclear
cell
pbmc
isol
heparin
whole
blood
densiti
gradient
centrifug
use
ficollpaqu
solut
ge
healthcar
sweden
store
liquid
nitrogen
pair
plasma
sampl
collect
determin
cytokin
concentr
merscovspecif
antibodi
respons
control
pbmc
obtain
healthi
person
nmc
although
viral
peptid
trigger
tcell
respons
merscov
infect
recent
identifi
entir
spectrum
viral
antigen
link
divers
major
histocompat
complex
molecul
remain
determin
studi
tcell
respons
sever
acut
respiratori
syndrom
coronaviru
sarscov
member
coronaviru
famili
elicit
similar
respiratori
infect
human
demonstr
structur
protein
spike
envelop
membran
nucleocapsid
immunogen
cell
compar
nonstructur
protein
thu
use
overlap
synthet
peptid
span
structur
protein
merscov
access
number
viral
antigen
analyz
tcell
respons
merscov
peptid
librari
compris
peptid
consist
overlap
amino
acid
residu
peptid
puriti
determin
mass
spectrometri
highperform
liquid
chromatographi
manufactur
mimotop
australia
dissolv
peptid
dimethyl
sulfoxid
dmso
concentr
mgml
pool
encompass
viral
protein
set
ntermin
peptid
ctermin
peptid
e
n
protein
set
emn
peptid
concentr
plasma
cytokineschemokin
tumor
necrosi
factor
alpha
interferon
gammainduc
protein
monocyt
chemoattract
protein
macrophag
inflammatori
regul
activ
normal
cell
express
secret
rant
quantifi
use
bioplex
multiplex
immunoassay
system
biorad
laboratori
hercul
california
accord
manufactur
instruct
plasma
interferon
ifn
measur
enzymelink
immunosorb
assay
elisa
use
verikineh
elisa
kit
pbl
assay
scienc
piscataway
new
jersey
antimerscov
immunoglobulin
igm
immunoglobulin
g
igg
plasma
titer
determin
use
indirect
immunofluoresc
test
elisa
kit
euroimmun
ag
lubeck
germani
respect
follow
manufactur
instruct
antimerscov
igm
titer
defin
greatest
dilut
show
identifi
specif
fluoresc
serial
dilut
start
plasma
sampl
analyz
amount
plasma
igg
evalu
semiquantit
calcul
ratio
extinct
valu
patient
sampl
calibr
suggest
manufactur
neutral
antibodi
ab
spike
protein
measur
pseudotyp
retrovirusbas
neutral
assay
describ
previous
neutral
ab
titer
present
highest
plasma
dilut
yield
inhibit
luciferas
activ
pbmc
cultur
complet
rpmi
medium
contain
vv
human
serum
biowest
nuaill
franc
stimul
peptid
presenc
monoclon
ab
mab
bd
bioscienc
hour
neg
posit
control
cultur
pbmc
incub
dmso
alon
mab
bd
bioscienc
respect
addit
brefeldin
ebiosci
monensin
bd
bioscienc
cell
incub
addit
hour
stain
dead
cell
use
livedead
fixabl
aqua
dead
cell
stain
kit
molecular
probe
cell
subject
surfac
stain
allophycocyanin
apc
mab
bd
bioscienc
detect
antigenreact
cell
degranul
activ
fluorescein
isothiocyan
fitc
mab
biolegend
ad
stimul
cultur
also
use
surfac
stain
fixat
permeabil
use
intracellular
fix
perm
set
ebiosci
cell
stain
either
set
pe
apc
set
phycoerythrincyanin
pe
fitc
mab
least
stain
cell
per
sampl
acquir
use
facsvers
flow
cytomet
bd
bioscienc
analyz
use
flowjo
softwar
tree
star
ashland
oregon
data
present
correspond
backgroundsubtract
result
use
neg
control
cultur
sum
respons
differ
peptid
pool
unless
otherwis
specifi
statist
analysi
perform
use
prism
version
softwar
graphpad
san
diego
california
nonparametr
mannwhitney
u
test
wilcoxon
signedrank
test
use
compar
group
independ
pair
sampl
respect
correl
analysi
carri
use
spearman
test
differ
consid
statist
signific
p
total
patient
enrol
studi
shown
tabl
patient
divid
group
depend
sever
ill
sever
diseas
n
includ
fatal
n
patient
requir
mechan
ventil
reliev
respiratori
failur
n
moder
diseas
n
compris
patient
radiolog
evid
pneumonia
without
respiratori
failur
mild
diseas
n
encompass
patient
asymptomat
report
symptom
fever
headach
cough
malais
without
distinct
pulmonari
lesion
report
previous
older
age
link
sever
diseas
tabl
p
addit
decreas
lymphocyt
observ
patient
sever
moder
diseas
especi
acut
phase
infect
supplementari
figur
estim
role
cytokin
chemokin
infect
merscov
measur
plasma
level
cytokin
bead
array
elisa
plasma
concentr
significantli
elev
acut
phase
infect
increas
severemoder
ill
respect
extent
correl
diseas
sever
declin
basal
level
convalesc
phase
figur
howev
detect
either
phase
patient
plasma
level
increas
patient
acut
stage
increas
proport
diseas
sever
antiinflammatori
cytokin
rare
detect
antimerscov
absinclud
igm
igg
neutral
abswer
detect
patient
except
case
sever
diseas
within
first
week
ill
convalesc
phase
patient
sever
moder
ill
develop
neutral
ab
respons
also
seen
igm
igg
overal
sever
ill
greater
antibodi
respons
detect
patient
convalesc
phase
mild
asymptomat
patient
rare
develop
antibodi
respons
mean
standard
deviat
fold
dilut
neutral
ab
sever
vs
moder
vs
mild
vs
vs
respect
p
figur
assess
tcell
respons
merscov
pbmc
patient
stimul
pool
viral
peptid
analyz
intracellular
cytokin
via
flow
cytometri
supplementari
figur
shown
repres
patient
healthi
donor
virusreact
cell
detect
cell
patient
healthi
donor
figur
detail
tcell
frequenc
rel
day
viru
exposur
symptom
onset
individu
patient
provid
supplementari
figur
summari
acut
stage
virusreact
cellsa
determin
secret
upon
antigen
stimulationwer
detect
patient
sever
group
moder
mild
group
figur
convalesc
phase
cell
appear
patient
regardless
sever
infect
unlik
cell
high
frequenc
cell
secret
andor
express
seen
sever
moder
subject
median
secret
rang
mild
case
acut
stage
infect
convalesc
phase
frequenc
antigenreact
cell
diminish
portion
patient
sever
moder
infect
figur
cell
secret
cytokin
triplet
consid
potent
produc
cytokin
mostli
identifi
cell
convalesc
phase
figur
also
address
whether
merscovreact
cell
produc
cytokin
thelper
type
cytotox
cell
type
expect
cell
predomin
cell
rare
tcell
popul
figur
next
analyz
reactiv
cell
differ
viral
protein
cell
react
protein
emn
protein
especi
acut
phase
infect
median
interquartil
rang
iqr
vs
iqr
p
slightli
cell
recogn
emn
protein
convalesc
phase
iqr
vs
iqr
p
figur
final
analyz
relationship
serolog
tcell
respons
individu
patient
convalesc
phase
signific
correl
igg
titer
virusreact
tcell
frequenc
signific
correl
also
found
frequenc
virusreact
cell
figur
earli
period
mer
data
reveal
initi
severityproport
proinflammatori
cytokinechemokin
secret
follow
antibodi
tcell
respons
patient
typic
host
respons
mani
acut
viral
infect
howev
one
peculiar
find
extraordinarili
high
frequenc
merscovreact
cell
observ
larg
proport
patient
sever
moder
ill
acut
stage
prior
detect
humor
tcell
respons
convalesc
phase
magnitud
tcell
respons
greatli
augment
actual
contract
case
basi
data
infer
ineffici
control
invad
merscov
bring
robust
inflammatori
cytotox
lymphocyt
ctl
respons
clear
invad
virion
also
destroy
lung
tissu
yield
pneumonia
associ
strong
inflammatori
respons
sever
form
merscov
infect
reveal
histolog
serolog
find
human
anim
studi
observ
reinforc
associ
thu
elev
serum
level
associ
inflammatori
process
recruit
inflammatori
cell
could
reflect
ongo
inflamm
infect
site
studi
deceas
patient
show
detect
tcell
respons
high
level
plasma
proinflammatori
cytokin
chemokin
acut
phase
infect
therefor
highli
probabl
inflammatori
reaction
would
damag
diseas
lung
tissu
absenc
ctl
respons
patient
interestingli
plasma
level
rant
detect
increas
convalesc
phase
infect
irrespect
diseas
sever
specul
late
increas
rant
might
associ
secret
chemokin
activ
virusreact
lymphocyt
report
explor
role
tcell
respons
merscov
infect
use
anim
model
examin
infect
mice
transient
express
human
receptor
reveal
tcell
respons
requir
viral
clearanc
interestingli
coleman
et
al
report
use
mous
model
express
endogen
promot
cell
may
contribut
merscovinduc
lung
patholog
potenti
pathogen
contribut
strong
ctl
respons
acut
phase
infect
also
demonstr
anim
influenza
viru
infect
data
also
suggest
pathogen
role
cell
human
merscov
infect
posit
pathway
induc
strong
tcell
respons
acut
phase
merscov
infect
antigen
stimul
caus
ineffici
remov
invad
viru
andor
larg
inoculum
viru
could
induc
rapid
prolifer
differenti
naiv
cell
absenc
cell
otherwis
could
due
heterolog
immun
memori
cellsactiv
prior
infect
unrel
virusescrossreact
merscov
antigen
studi
need
address
possibl
spectrum
immun
respons
merscov
infect
appear
similar
sarscov
infect
report
sar
lymphodeplet
occur
patient
sever
mer
acut
phase
infect
moreov
magnitud
innat
immun
responserepres
serum
level
inflammatori
cytokin
chemokinesand
humor
immun
respons
reveal
increas
proport
diseas
sever
sarscov
merscov
infect
studi
demonstr
similar
bcell
respons
tcell
respons
merscov
infect
also
elev
severemoder
case
compar
mild
infect
lack
data
kinet
tcell
respons
sarscov
infect
numer
studi
investig
memori
tcell
respons
recov
sarscov
patient
among
comprehens
studi
tcell
respons
sarscov
protein
show
domin
tcell
respons
cell
line
find
merscov
though
observ
made
differ
time
point
howev
major
protein
recogn
cell
seem
differ
sarscov
merscov
tcell
respons
sarscov
cluster
mainli
spike
protein
cell
patient
merscov
respond
slightli
emn
rather
protein
differ
like
due
differ
time
point
tcell
respons
analyz
recognit
pattern
memori
cell
observ
merscov
patient
year
postinfect
unpublish
data
accord
recent
studi
conduct
zhao
et
al
examin
tcell
respons
patient
month
figur
correl
cell
antibodi
respons
plasma
immunoglobulin
g
titer
frequenc
interferon
cell
patient
plot
spearman
rank
correl
coeffici
correspond
p
valu
line
best
fit
shown
abbrevi
igg
immunoglobulin
g
postmerscov
infect
virusspecif
neutral
antibodi
tcell
respons
correl
sever
diseas
correl
also
observ
earli
convalesc
phase
infect
studi
howev
differ
interpret
regard
tcell
respons
base
find
patient
mild
subclin
ill
develop
promin
virusspecif
tcell
respons
zhao
et
al
propos
measur
merscovspecif
tcell
respons
may
use
make
prognos
studi
use
acut
stage
sampl
suggest
poor
prognosi
virusspecif
tcell
respons
detect
acut
phase
infect
nevertheless
presenc
virusspecif
cell
acut
phase
infect
shown
patient
sever
moder
ill
reliabl
biomark
poor
outcom
patient
cohort
provid
uniqu
opportun
studi
immun
respons
earli
period
merscov
infect
patient
believ
expos
merscov
antigen
first
time
live
thu
assum
antimerscov
immun
respons
measur
studi
would
primari
immun
respons
moreov
time
cours
antigen
exposur
symptom
onset
rel
well
defin
patient
due
sudden
outbreak
merscov
south
korea
limit
number
patient
recruit
studi
howev
obstacl
reach
conclus
anoth
weak
studi
absenc
viral
load
data
consequ
could
defin
relationship
antigen
dose
magnitud
cellular
immun
respons
nevertheless
studi
provid
valuabl
inform
cellular
immun
respons
merscov
infect
human
earli
period
infect
supplementari
materi
avail
clinic
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
